Abstract 74P
Background
ERBB2, a receptor tyrosine kinase, is commonly affected by mutations, amplifications, and overexpression in various types of cancers. Drugs targeting ERBB2 are gradually being promoted to various types of cancer. However, the variation of ERBB2 in Chinese population and the relationship between ERBB2 high expression abnormalities and the tumor immune microenvironment remains unclear.
Methods
We utilized genomic data from over 10,000 pan-cancer Chinese populations in CbioPortal to detect somatic mutations and copy number variations. We also performed RNA sequencing date in TCGA (pan-cancer Atlas studies) to determine ERBB2 expression in diverse cancer types and evaluate the immune gene characteristics and content of tumor-infiltrating immune cell populations.
Results
A total of 309 ERBB2 amplifications, 169 ERBB2 substitution or insertion deletions, and 28 ERBB2 fusions or rearrangements were detected in 10,194 patients. The ERBB2 amplification rate of breast cancer (23.84%), gallbladder cancer (13.75%) and urothelium cancer (8.33%) ranked the top three among all cancer types. Among the co-mutated genes with ERBB2 mutations, TP53 (68.8%), CDK12 (34.7%), and RARA (18.7%) have the highest proportion of mutations. Furthermore, among 10,967 RNA datasets in TCGA, breast cancer, esophageal squamous cell carcinoma, and gastric adenocarcinoma displayed the highest average expression levels of ERBB2. Patients with high ERBB2 expression exhibited similar TMB values to those with low ERBB2 expression. However, in breast cancer, colon cancer, lung adenocarcinoma and lung squamous carcinoma, ERBB2 high expression was significantly associated with a higher proportion of activated mast cells, monocytes, and regulatory T cells, while the percentage of resting mast cells and M1 macrophages was notably lower.
Conclusions
Our study identified ERBB2 variation patterns among a cohort of Chinese solid tumor patients and demonstrated that ERBB2 abnormality high expression is associated with an activated immune system and a stronger inflammatory response. Our findings offer insights into the potential benefits of using immune checkpoint inhibitors for this type of patient.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
45P - Therapeutic potential of ISM8207: A novel QPCTL inhibitor, in triple-negative breast cancer and B-cell non-Hodgkin lymphoma
Presenter: Sujata Rao
Session: Poster session 09
46P - Effect of coadministration of antioxidant chlorophyllin with docetaxel on invasion and metastasis in triple-negative breast cancer in vivo/in vitro
Presenter: Ayse Burus
Session: Poster session 09
47P - An ozone delivery system by cisplatin prodrug self-assembling micelles combining microwave to sensitizing immune checkpoint inhibitor in triple-negative breast cancer
Presenter: Dan Zheng
Session: Poster session 09
48P - Non-steroid anti-inflammatory treatment enhances the efficacy of modulated electro hyperthermia on triple-negative breast cancer and melanoma cancer models in vivo
Presenter: Nino Giunashvili
Session: Poster session 09
49P - Circulating miRNA signatures to predict recurrence in patients with pathological complete response of triple-negative breast cancer
Presenter: Ana Julia de Freitas
Session: Poster session 09
50P - Application and mechanism of tarloxotinib in HER2-positive breast cancer
Presenter: Xinyi Shao
Session: Poster session 09
51P - Nanoengineered sonosensitive platelets for synergistically augmented sonodynamic breast tumour therapy by glutamine deprivation and cascading thrombosis
Presenter: Liqiang Zhou
Session: Poster session 09
53P - Treatment of cancer cells based on circulating tumor cell’s expression profile using off-label drugs
Presenter: Panagiotis Apostolou
Session: Poster session 09
54P - Enhanced oxidative phosphorylation of metastasis-initiating cells facilitates esophageal tumor cell seeding in lymph nodes
Presenter: Shanshan Li
Session: Poster session 09
55P - Transcriptional profiles of engineered T cells stimulated with different receptor structures and co-stimulatory domains
Presenter: Ungue Shin
Session: Poster session 09